Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
about
A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implicationsDoxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.Perspective on the dynamics of cancer.Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
P2860
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@ast
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@en
type
label
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@ast
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@en
prefLabel
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@ast
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@en
P2093
P2860
P356
P1476
Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
@en
P2093
David Goukassian
Giannoula L Klement
James P Morgan
Joseph Carrozza
Lynn Hlatky
Xinhua Yan
P2860
P356
10.3389/FPHAR.2012.00113
P577
2012-06-27T00:00:00Z